Tetra Radar · FDA Approvals · Decision date
UX111: FDA decision date
Ultragenyx Pharmaceutical Inc (RARE) · 19 September 2026
The FDA granted the BLA Priority Review and assigned a PDUFA action date of September 19, 2026.
Source: 10-Q of 5 August 2026
The FDA approved it on 17 September 2026.
The FDA approved Fayuvi for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function.
Ultragenyx Pharmaceutical Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.